Abstract: Provided are a method for predicting a risk of deterioration of a pathogenic condition of a patient suffering a coronavirus disease (COVID-19), especially a severe patient suffering a COVID-19 and a kit thereof. The method of the present application may effectively predict the deterioration of the pathogenic condition of the patient suffering a COVID-19, thereby carrying out clinical intervention in advance, to improve prognosis of the patient suffering a COVID-19. The present application finds for the first time that the level of a heparin-binding protein (HBP) can be used as a significant indicator for early predicting relapse of the patient suffering a COVID-19, expression time of an HBP indicator is around 5 days earlier than that of a series of other clinical indicators, and thus the HBP indicator particularly has a clinical value.

Abstract: The present invention provides a use of a phillyrin/phillygenin composition which targets and inhibits 3CLpro protein of COVID-19 virus, in preparation of an anti-coronavirus drug or a drug for treating a disease caused by the coronavirus, wherein the coronavirus is COVID-19 virus, and the disease caused by the coronavirus is COVID-19.

Abstract: A compound including a structure of Formula (I) and a preparation method thereof, wherein R1 is —OH, —CH2OH, or —OCOCH3; R2, R3, and R4 are independently —H, —CH3 or —F, and at least one of R2, R3, and R4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.

Abstract: A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth.

Abstract: A compound including a structure of Formula (I) and a preparation method thereof, wherein R1 is —OH, —CH2OH, or —OCOCH3; R2, R3, and R4 are independently —H, —CH3 or —F, and at least one of R2, R3, and R4 is —F. A method for treating a subject suffering from a viral disease includes administering an effective amount of said compound or a solvate thereof to the subject.

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.

Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.

Abstract: Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.

Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.

Abstract: A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth.

Abstract: Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.

Abstract: Provided is a method for treating adenoid cystic carcinoma by using a pharmaceutical composition including benzenesulfonamide derivatives and pharmaceutically acceptable carriers.

Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.

Abstract: Provided is a method for treating adenoid cystic carcinoma by using a pharmaceutical composition including benzenesulfonamide derivatives and pharmaceutically acceptable carriers.

Abstract: The present invention relates to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for treating coughing, and more specifically to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for preventing and relieving coughing and eliminating airway inflammation. Experiments demonstrate that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times of a guinea pig with increased cough sensitivity induced by cigarette smoke and an acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and significantly reduce the airway inflammation of the guinea pig with increased cough susceptibility induced by cigarette smoke, so that the Fructus schisandrae total polysaccharides can be used for preparing drugs for preventing cough, relieving cough and eliminating airway inflammation.

Abstract: The present invention relates to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for treating coughing, and more specifically to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for preventing and relieving coughing and eliminating airway inflammation. Experiments demonstrate that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times of a guinea pig with increased cough sensitivity induced by cigarette smoke and an acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and significantly reduce the airway inflammation of the guinea pig with increased cough susceptibility induced by cigarette smoke, so that the Fructus schisandrae total polysaccharides can be used for preparing drugs for preventing cough, relieving cough and eliminating airway inflammation.

Abstract: A process of using Isatis root polysaccharide in the manufacture of medicaments for treating and/or preventing diseases induced by influenza virus and complications thereof, wherein the molecular weight of the Isatis root polysaccharide is 3000-7000 Da, and the influenza viruses include influenza virus A, influenza virus B, avian influenza virus, such as human influenza virus H1N1, H3N2, avian influenza virus H6N2, H7N3, H9N2 and INF B. The mechanism of the Isatis root polysaccharide against influenza virus is due to the ability to inhibit the attachment of influenza virus to the host cell. The present invention also discloses a pharmaceutical composition containing the above-mentioned Isatis root polysaccharides and a method for preparing the polysaccharides.